Evidence-Based Recommendations for Education Provided to Patients and Families Regarding the Adverse Events of ALK and MEK Inhibitors: A Systematic Review From the Children's Oncology Group
Conclusions: Adverse events of ALK and MEK inhibitors differ from the more common adverse events experienced with conventional treatment modalities used in pediatric oncology. It is important for nurses to include information regarding potential adverse events in patient/family education for children receiving these targeted agents.PMID:38549368 | DOI:10.1177/27527530231206101 (Source: Ann Oncol)
Source: Ann Oncol - March 29, 2024 Category: Cancer & Oncology Authors: Beth Fisher Ashley Meyer Anastasia Brown Mary Conway Keller Tara McKeown Jennifer Tiller Kate M Saylor Elizabeth A Duffy Source Type: research
A Proposal for Standardization of Early Outcomes Following Robot-Assisted Radical Cystectomy (RARC): RARC Tetrafecta
CONCLUSIONS: RARC tetrafecta could be a comprehensive method for reporting early outcomes in patients undergoing RARC, with improvements aligned with the surgeon's experience.PMID:38538821 | DOI:10.1245/s10434-024-15138-7 (Source: Ann Oncol)
Source: Ann Oncol - March 28, 2024 Category: Cancer & Oncology Authors: Wan Song Jiwoong Yu Jae Hoon Chung Minyong Kang Hyun Hwan Sung Hwang Gyun Jeon Seong Il Seo Seong Soo Jeon Byong Chang Jeong Source Type: research
The Association Between Oncology Outreach and Timely Treatment for Rural Patients with Breast Cancer: A Claims-Based Approach
CONCLUSIONS: Our findings indicate that preoperative outreach is protective against surgical delay. The traveling oncologists who enable such outreach may play an integral role in catalyzing the coordination and timeliness of patient-centered care.PMID:38538822 | DOI:10.1245/s10434-024-15195-y (Source: Ann Oncol)
Source: Ann Oncol - March 28, 2024 Category: Cancer & Oncology Authors: Bruno T Scodari Andrew P Schaefer Nirav S Kapadia Gabriel A Brooks A James O'Malley Erika L Moen Source Type: research
The Potential of Wearable Devices in Cancer Care Delivery
JAMA Oncol. 2024 Mar 28. doi: 10.1001/jamaoncol.2024.0001. Online ahead of print.NO ABSTRACTPMID:38546699 | DOI:10.1001/jamaoncol.2024.0001 (Source: Ann Oncol)
Source: Ann Oncol - March 28, 2024 Category: Cancer & Oncology Authors: Sarah T Hawley Megan R Haymart Source Type: research
Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma (RCT, CSGO-HBP-015)
CONCLUSIONS: This study found that GA and GS are viable neoadjuvant treatment regimens in R/BR-PDAC. Although the GA group exhibited a favorable PFS outcome, the primary endpoint was not achieved.PMID:38546797 | DOI:10.1245/s10434-024-15199-8 (Source: Ann Oncol)
Source: Ann Oncol - March 28, 2024 Category: Cancer & Oncology Authors: Daisaku Yamada Shogo Kobayashi Hidenori Takahashi Yoshifumi Iwagami Hirofumi Akita Kei Asukai Junzo Shimizu Terumasa Yamada Masahiro Tanemura Shigekazu Yokoyama Masanori Tsujie Tadafumi Asaoka Yutaka Takeda Osakuni Morimoto Akira Tomokuni Yuichiro Doki Hi Source Type: research
Letter to the Editor Regarding the Article, "Development of a Nomogram to Predict Clinically Relevant Postoperative Pancreatic Fistula After Pancreaticoduodenectomy on the Basis of Visceral Fat Area and Magnetic Resonance Imaging: A Nomogram Incorporating the Inflammatory Burden Index and Drainage Fluid Amylase Levels"
Ann Surg Oncol. 2024 Mar 28. doi: 10.1245/s10434-024-15159-2. Online ahead of print.NO ABSTRACTPMID:38546798 | DOI:10.1245/s10434-024-15159-2 (Source: Ann Oncol)
Source: Ann Oncol - March 28, 2024 Category: Cancer & Oncology Authors: Jiayue Zou Xiaofeng Xue Lei Qin Source Type: research
ASO Author Reflections: The Impact of DCIS on Positive Margin Rates
Ann Surg Oncol. 2024 Mar 28. doi: 10.1245/s10434-024-15217-9. Online ahead of print.NO ABSTRACTPMID:38546799 | DOI:10.1245/s10434-024-15217-9 (Source: Ann Oncol)
Source: Ann Oncol - March 28, 2024 Category: Cancer & Oncology Authors: Hemali Chauhan Hutan Ashrafian Zoltan Takats Daniel Richard Leff Source Type: research
ASO Visual Abstract: High Community-Level Social Vulnerability is Associated with Worse Recurrence-Free Survival Following Resection of Extremity and Truncal Soft-Tissue Sarcoma
Ann Surg Oncol. 2024 Mar 28. doi: 10.1245/s10434-024-15201-3. Online ahead of print.NO ABSTRACTPMID:38546800 | DOI:10.1245/s10434-024-15201-3 (Source: Ann Oncol)
Source: Ann Oncol - March 28, 2024 Category: Cancer & Oncology Authors: Raymond S Traweek Heather Lyu Russell G Witt Rebecca A Snyder Elise F Nassif David D Krijgh Jeffrey M Smith Gordon S Tilney Chun Feng Yi-Ju Chiang Keila E Torres Margaret J Roubaud Christopher P Scally Kelly K Hunt Emily Z Keung Alexander F Mericli Christ Source Type: research
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
Lancet Oncol. 2024 Apr;25(4):439-454. doi: 10.1016/S1470-2045(24)00064-0.ABSTRACTBACKGROUND: DESTINY-Lung01 is a multicentre, open-label, phase 2 study evaluating the antitumour activity and safety of trastuzumab deruxtecan, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpressing or HER2 (ERBB2)-mutant unresectable or metastatic non-small-cell lung cancer (NSCLC). The results of the HER2-mutant cohort (cohort 2) have been reported elsewhere. Herein, we report the primary analysis of cohorts 1 and 1A, which aimed to evaluate the activity and safety of trastuzumab deruxtecan 5·4 mg/kg and 6·4 mg/kg in...
Source: Ann Oncol - March 28, 2024 Category: Cancer & Oncology Authors: Egbert F Smit Enriqueta Felip Dipesh Uprety Misako Nagasaka Kazuhiko Nakagawa Luis Paz-Ares Rodr íguez Jose M Pacheco Bob T Li David Planchard Christina Baik Yasushi Goto Haruyasu Murakami Andreas Saltos Kaline Pereira Ayumi Taguchi Yingkai Cheng Qi Yan Source Type: research
Reporting and analysis of immunotherapy trials adverse events: what is going wrong, how to do better?
Ann Oncol. 2024 Mar 26:S0923-7534(24)00083-8. doi: 10.1016/j.annonc.2024.03.006. Online ahead of print.NO ABSTRACTPMID:38548063 | DOI:10.1016/j.annonc.2024.03.006 (Source: Ann Oncol)
Source: Ann Oncol - March 28, 2024 Category: Cancer & Oncology Authors: I Pourmir R Nebbache S Champiat O Lambotte Cancer Immunotherapy Adverse Events Working Group Source Type: research
ASO Author Reflections: Advancing Early Outcome Assessment in Robot-Assisted Radical Cystectomy: RARC Tetrafecta
Ann Surg Oncol. 2024 Mar 27. doi: 10.1245/s10434-024-15169-0. Online ahead of print.NO ABSTRACTPMID:38536582 | DOI:10.1245/s10434-024-15169-0 (Source: Ann Oncol)
Source: Ann Oncol - March 27, 2024 Category: Cancer & Oncology Authors: Wan Song Jiwoong Yu Byong Chang Jeong Source Type: research
ASO Author Reflections: Lymphoedema Related to Inguinal and Ilioinguinal Lymphadenectomy for Melanoma
Ann Surg Oncol. 2024 Mar 27. doi: 10.1245/s10434-024-15216-w. Online ahead of print.NO ABSTRACTPMID:38536583 | DOI:10.1245/s10434-024-15216-w (Source: Ann Oncol)
Source: Ann Oncol - March 27, 2024 Category: Cancer & Oncology Authors: T S Lee A J Spillane Source Type: research
Complications of Outpatient Chest Tube Management for Prolonged Air Leaks After Pulmonary Surgery
CONCLUSIONS: One-way valve device use has a substantial complication rate, and chest tube duration is a risk factor. In-hospital interventions might benefit patients with larger leaks that likely require prolonged OWD use. Because clamp trials occasionally fail, we contend that a clamp trial is the safest course before CT removal.PMID:38536584 | DOI:10.1245/s10434-024-15219-7 (Source: Ann Oncol)
Source: Ann Oncol - March 27, 2024 Category: Cancer & Oncology Authors: Ryan J Randle Prasha Bhandari Hao He Mark F Berry Leah M Backhus Natalie S Lui Douglas Z Liou Joseph B Shrager Source Type: research
The Key Role of Tumor Budding in Predicting the Status of Lymph Node Involvement in Early Gastric Cancer Patients: A Clinical Multicenter Validation in China
CONCLUSIONS: Tumor budding is a robust predictor of LN involvement in EGC. The incorporation of tumor budding into a nomogram is an effective strategy, thereby informing and enhancing clinical decision-making.PMID:38536585 | DOI:10.1245/s10434-024-15229-5 (Source: Ann Oncol)
Source: Ann Oncol - March 27, 2024 Category: Cancer & Oncology Authors: Xiangyu Wang Xiuding Yang Fenglin Cai Mingzhi Cai Yong Liu Li Zhang Rupeng Zhang Fangqin Xue Yan Sun Jingyu Deng Source Type: research
Prevalence of and Factors Associated with Financial Toxicity After Pancreatectomy and Gastrectomy
CONCLUSIONS: Patients with upper gastrointestinal cancer have a major risk of FT. In addition to predicting the FT risk before surgery, facilitating quicker functional recovery with the appropriate use of MIS is considered important to reducing the FT risk.PMID:38536586 | DOI:10.1245/s10434-024-15236-6 (Source: Ann Oncol)
Source: Ann Oncol - March 27, 2024 Category: Cancer & Oncology Authors: Yuki Hirata Connie To Heather Lyu Grace L Smith Joyce P Samuel Hop S Tran Cao Brian D Badgwell Matthew H G Katz Naruhiko Ikoma Source Type: research
